What baseline laboratory and clinical workup is required before initiating azathioprine therapy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Baseline Workup for Azathioprine

Before initiating azathioprine, you must obtain TPMT activity testing, complete blood count with differential, liver function tests including transaminases, and renal function tests 1, 2.

Essential Laboratory Tests

TPMT Testing (Mandatory)

  • TPMT activity must be checked in all patients prior to receiving azathioprine 1
  • This is a Strength A recommendation with level 1+ evidence
  • TPMT phenotyping (red blood cell TPMT activity) is the standard approach
  • TPMT genotyping is only required for patients with:
    • Indeterminate/borderline phenotype values
    • Recent blood transfusions (which invalidate phenotyping results) 1, 2
  • Consider NUDT15 genotyping, particularly in patients of East Asian ancestry (2% have two loss-of-function alleles, 21% have one) 2

Critical caveat: TPMT testing cannot substitute for ongoing CBC monitoring—both are required 2

Baseline Blood Work

The following must be obtained before starting therapy 1:

  • Complete blood count (CBC) with differential white cell count
  • Liver function tests including transaminases (ALT or AST)
  • Renal function tests

Clinical Assessment

Screen for Absolute Contraindications

Evaluate for 1:

  • Hypersensitivity to azathioprine or 6-mercaptopurine
  • Severe active infections
  • Severely impaired hepatic or bone marrow function
  • Active pancreatitis
  • Known malignancy (relative contraindication—immunosuppression may accelerate disease progression)
  • Pregnancy (relative contraindication unless benefits outweigh risks)
  • Lactation

Viral Hepatitis Screening

  • Check hepatitis B surface antigen (HBsAg) in all patients 1
  • Approximately one-third of the world's population has serological evidence of HBV exposure
  • HBsAg-positive patients are at risk for disease flare with immunosuppression
  • Transaminases alone do not reliably detect all infected individuals 1

Varicella Exposure History

  • Document chickenpox/varicella history 3
  • Patients without prior chickenpox require immediate attention if exposed during therapy for consideration of zoster immune globulin

Medication Review

Critical Drug Interactions to Identify

Document current use of 2:

  • Allopurinol or febuxostat (xanthine oxidase inhibitors): Requires dose reduction of azathioprine to 1/3 to 1/4 usual dose; febuxostat concomitant use not recommended
  • Aminosalicylates (sulfasalazine, mesalazine, olsalazine): Inhibit TPMT—use with caution
  • Warfarin: Azathioprine may inhibit anticoagulant effect
  • ACE inhibitors: Can induce severe leukopenia when combined with azathioprine
  • Co-trimoxazole or other myelosuppressive drugs: May cause exaggerated leukopenia
  • Ribavirin: Induces severe pancytopenia—avoid combination

Vaccination Status

  • Live vaccines are contraindicated 1, 3
  • Household members should receive inactive (not live) polio vaccine due to orofecal transmission risk

Special Populations

Renal Impairment

  • Use lower end of normal dosage range 1
  • Monitor CBC more carefully
  • No dose adjustment needed for hemodialysis patients

Hepatic Disease

  • Use cautiously with regular monitoring 1
  • Reduce dosage if hepatic or hematological toxicity occurs

Patient Counseling Requirements

Before initiating therapy, document discussion of 3:

  • Slow onset of action (2-3 months for benefit)
  • Need for frequent blood monitoring (weekly initially)
  • Signs of bone marrow suppression (unexplained bruising, sore throat, fever)
  • Signs of hepatotoxicity (jaundice)
  • Hypersensitivity symptoms may mimic flu
  • Small increased malignancy risk with long-term use
  • Pregnancy avoidance
  • Drug interactions
  • Varicella exposure precautions

Common pitfall: Failing to check TPMT before starting therapy. Approximately 0.3% of patients have complete TPMT deficiency and will develop life-threatening myelosuppression on standard doses 2, 4. An additional 10% have intermediate activity requiring dose modification 2.

Related Questions

Why is thiopurine methyltransferase (TPMT) testing needed for patients on certain drugs?
For a patient with dermatomyositis initiating azathioprine, which laboratory tests should be obtained and monitored?
What is the appropriate azathioprine dosing regimen for a patient with inflammatory myositis on high‑dose corticosteroids, including initial dose, titration, thiopurine methyltransferase (TPMT) testing, monitoring, and alternatives if not tolerated?
What lab tests are recommended for patients on Azathioprine (Imuran)?
What is the appropriate use, dosing, and monitoring of azathioprine for maintenance therapy in adult inflammatory bowel disease (Crohn’s disease or ulcerative colitis)?
What diagnostic tests and initial management steps should be taken for a patient with clinical and subtle histologic findings suggesting keratosis pilaris atrophicans faciei, with differential diagnoses of quiescent discoid lupus erythematosus and quiescent poikilodermatous dermatomyositis?
In a 15-year-old patient weighing 71.5 kg in the emergency department, is a single intravenous push of 60 mg propofol appropriate for induction?
What are the side effects of daily calcitriol (active vitamin D) dosing?
What are the real indications for calcitriol 0.25 µg?
Can the tuberculin skin test (TST) and the anti‑rabies virus vaccine be administered simultaneously, or is an interval required between them?
Can a beta‑blocker be used in a patient with chronic kidney disease and left ventricular hypertrophy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.